Evidence map›Paper›PMID 39915890›Full record

ArticleMobile DNA2025

Targeted detection of endogenous LINE-1 proteins and ORF2p interactions.

Mathias I Nielsen, Justina C Wolters, Omar G Rosas Bringas, Hua Jiang, Luciano H Di Stefano, Mehrnoosh Oghbaie, Samira Hozeifi, Mats J Nitert, Alienke van Pijkeren, Marieke Smit and 6 more

Abstract read
In one paragraph

Article in Mobile DNA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cancer cells subvert the primate-specific KRAB zinc finger protein ZNF93 to control APOBEC3B.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mathias I Nielsen *Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
Justina C Wolters *Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. j.c.wolters@umcg.nl.
Omar G Rosas BringasEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Hua JiangLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
Luciano H Di StefanoEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Mehrnoosh OghbaieLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
Samira HozeifiEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Mats J NitertDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Alienke van PijkerenDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Marieke SmitDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Lars Ter MorscheLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
Apostolos MourtzinosLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
Vikram DeshpandeDepartment of Pathology, Mass General Brigham and Harvard Medical School, Boston, MA, USA.
Martin S TaylorDepartment of Pathology, Mass General Brigham and Harvard Medical School, Boston, MA, USA.
Brian T ChaitLaboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY, USA.
John LaCavaLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA. jlacava@rockefeller.edu.

Funding

RESEARCH TRAINING IN RHEUMATOLOGYT32AR007108 · NIAMS · UNIVERSITY OF WASHINGTON · PI Shaun Jackson, Tomas M Mustelin · 1986 to 2026
$6.6M
Defining molecular contributions of LINE-1 retrotransposons to AD / ADRDR01AG078925 · NIA · ROCKEFELLER UNIVERSITY · PI John LaCava, John M Sedivy · 2022 to 2026
$3.7M
Demonstrating interactome-level connections between Alzheimer disease, LINE-1 retrotransposons, and cellular senescenceR01GM126170 · NIGMS · ROCKEFELLER UNIVERSITY · PI LACAVA, JOHN · 2018 to 2021
$2.4M
Upstream drivers of type I interferons in lupusR01AI186337 · NIAID · UNIVERSITY OF WASHINGTON · PI Joanne Michelle Kahlenberg, John LaCava · 2024 to 2026
$2.3M
Elucidating structural, mechanistic, and allosteric determinants of mTOR Complex 2 (mTORC2) signaling.K08DK129824 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI TAYLOR, MARTIN S · 2021 to 2025
$853k
NIAID NIH HHS R01 AI186337NIAMS NIH HHS T32 AR007108NIA NIH HHS R01 AG078925NIDDK NIH HHS K08 DK129824NIGMS NIH HHS R01 GM126170
6 · The paper itself

Abstract

backgroundBoth the expression and activities of LINE-1 (L1) retrotransposons are known to occur in numerous cell-types and are implicated in pathobiological contexts such as aging-related inflammation, autoimmunity, and in cancers. L1s encode two proteins that are translated from bicistronic transcripts. The translation product of ORF1 (ORF1p) has been robustly detected by immunoassays and shotgun mass spectrometry (MS). Yet, more sensitive detection methods would enhance the use of ORF1p as a clinical biomarker. In contrast, until now, no direct evidence of endogenous L1 ORF2 translation to protein (ORF2p) has been shown. Instead, assays for ORF2p have been limited to ectopic L1 ORF over-expression contexts and to indirect detection of endogenous ORF2p enzymatic activity, such as by the sequencing of de novo genomic insertions. Immunoassays for endogenous ORF2p have been problematic, producing apparent false positives due to cross-reactivities, and shotgun MS has not yielded reliable evidence of ORF2p peptides in biological samples.

resultsHere we present targeted mass spectrometry assays, selected and parallel reaction monitoring (SRM and PRM, respectively) to detect and quantify L1 ORF1p and ORF2p at their endogenous abundances. We were able to quantify ORF1p and ORF2p present in our samples down to a range in the low attomoles. Confident in our ability to affinity enrich ORF2p, we describe an interactome associated with endogenous ORF2-containing macromolecular assemblies.

conclusionsThis is the first assay to demonstrate sensitive and robust quantitation of endogenous ORF2p. The ability to assay ORF2p directly and quantitatively will improve our understanding of the developmental and diseased cell states where L1 expression and its activity naturally occur. The ability to simultaneously assay endogenous L1 ORF1p and ORF2p is an important step forward for L1 analytical biochemistry. Endogenous ORF2p interactomes can now be presented with confidence that ORF2p is among the enriched proteins.

Indexed as

CancerLINE-1Mass spectrometryPRMRetrotransposonSRMTargeted proteomics

Identifiers

PMID39915890
PMCPMC11800616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.